COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Effects of Tegaserod vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00277550
Recruitment Status : Withdrawn
First Posted : January 16, 2006
Last Update Posted : March 4, 2016
Mayo Clinic
Information provided by (Responsible Party):

Brief Summary:
To demonstrate the effects of tegaserod on gastrointestinal scintigraphic orocecal transit in female patients with CC and upper GI symptoms of dyspepsia

Condition or disease Intervention/treatment Phase
Constipation and Dyspepsia Drug: Tegaserod and Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Evaluation of the Effects of Tegaserod (6 mg b.i.d) on Whole Gut Transit Time in Patients With Chronic Idiopathic Constipation and Dyspepsia

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. To determine the effect of one week of tegaserod on the passage of content through the gut by radiological procedures.

Secondary Outcome Measures :
  1. To evaluate the PD effects of tegaserod on upper & lower GI transit
  2. To evaluate global well-being & upper and lower GI symptoms in daily assessment of bowel habits and weekly global and individual symptom assessments

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Females aged 18 to 64 years of age
  • Patients must present with two or more of the following criteria for chronic constipation for at least 12 weeks prior to entering the study:

    1. Less than 3 bowel movements per week
    2. Hard or lumpy stools
    3. Straining during bowel movements
    4. Feeling of incomplete evacuation
  • Patients must report overlapping symptoms consistent with dyspepsia, such as mid-upper abdominal discomfort characterized by early satiety, post-meal fullness and bloating

Exclusion Criteria:

  • Patients with a recent history of, or current frequency of diarrhea occuring more than once per month off of laxatives
  • Clinically significant diagnosis of pelvic outlet obstruction or pelvic floor dyssenergia as determined by the study physicians
  • Patients with constipation secondary to medication use as determined by the study physician
  • Patients with clinically significant abnormal TSH levels at screening
  • Patients that have heartburn or abdominal pain as their predominant GI symptom
  • Evidence of cathartic colon or a history of laxative abuse

    • Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00277550

Sponsors and Collaborators
Mayo Clinic
Layout table for investigator information
Principal Investigator: Nicholas Talley, MD Mayo Clinic
Principal Investigator: Michael Crowell, PhD Mayo Clinic

Layout table for additonal information
Responsible Party: Novartis Identifier: NCT00277550    
Other Study ID Numbers: CHTF919EUS42
First Posted: January 16, 2006    Key Record Dates
Last Update Posted: March 4, 2016
Last Verified: March 2016
Keywords provided by Novartis:
Constipation, Tegaserod, Dyspepsia
Additional relevant MeSH terms:
Layout table for MeSH terms
Signs and Symptoms, Digestive
Signs and Symptoms
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs